Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.31 |
| ▸ | MELK | Q14680 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13137162 | 0.87 | HDAC1 (0.39) | HDAC1HDAC8HDAC6QPCTQPCTL | |
| Hydrochloric Acid SCHEMBL3047357 | 0.86 | HDAC1 (0.39) | HDAC1HDAC8HDAC6QPCTQPCTL | |
| SCHEMBL13137127 | 0.85 | CHEK1 (0.35) | QPCTTNIK | |
| SCHEMBL13137251 | 0.85 | MAP4K1 (0.39) | HDAC1HDAC8HDAC6QPCTQPCTL | |
| Hydrochloric Acid SCHEMBL3048045 | 0.84 | CHEK1 (0.34) | QPCTTNIK | |
| Hydrochloric Acid SCHEMBL3040214 | 0.84 | HDAC1 (0.37) | HDAC1HDAC8HDAC6QPCTMELK | |
| SCHEMBL13137177 | 0.83 | HDAC1 (0.39) | ABL1HDAC1HDAC8HDAC6QPCT | |
| Hydrochloric Acid SCHEMBL3044450 | 0.82 | HDAC1 (0.38) | ABL1HDAC1HDAC8HDAC6QPCT | |
| SCHEMBL13137179 | 0.82 | OPRL1 (0.33) | MELKS1PR1 | |
| SCHEMBL13137169 | 0.82 | GRIN2B (0.34) | QPCTMELKS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | ABL1 4043/4885HDAC1 2221/4885HDAC8 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.